10-K: Scientist Home Faces Going Concern Doubt Amidst Losses

Scientist Home Future Health Limited reported a significant net loss and net current liabilities for fiscal year 2025, raising substantial doubt about its ability to continue as a going concern, despite revenue growth and expansion plans.

Summary

• Scientist Home Future Health Limited, a Nevada corporation, operates through its Hong Kong subsidiary, Scientist Home HK, specializing in retail trading of health supplements and topical creams, and provision of physical check-up services.
• The company generated $204,055 in revenue for the fiscal year ended December 31, 2025, an increase from $120,775 in the period ended December 31, 2024.
• A net loss of $231,725 was incurred for FY2025, significantly higher than the $14,980 net loss in FY2024.
• As of December 31, 2025, the company reported net current liabilities of $22,212.
• The independent registered public accounting firm expressed "substantial doubt about the Company's ability to continue as a going concern."
• The company plans to expand its operations by establishing physical health centers in Hong Kong (opened November 2025) and Singapore (expected within six months, funds permitting).
• During FY2025, the company issued 236,000 shares of common stock at $1.5 per share, raising aggregate gross proceeds of $354,000.
• Material weaknesses in internal control over financial reporting were identified, including insufficient segregation of duties, absence of an independent board or audit committee, and lack of written internal control policies.
• Products offered include Vein Cream, Calcification Cream, Spermaceti Cream, Bone Gelatine Hydrolysate, Mixed Gelatine Hydrolysate, and High Concentration Proteinase, with the company noting no scientific evidence to support health claims, which are based on company opinion/belief.
• The company sources its proprietary products from Scientist Home Limited, a related party in which CEO Mr. Chan Siu Hung is the sole shareholder and director.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this as highly negative due to the explicit going concern warning from the auditor, significant net losses, and identified material weaknesses in internal controls, which overshadow any revenue growth or expansion plans.

Positives

• Revenue increased from $120,775 in 2024 to $204,055 in 2025, demonstrating business growth.
• The company successfully opened a physical health center in Hong Kong in November 2025 and plans to establish another in Singapore within six months, indicating strategic expansion.
• The product line has been broadened with the addition of over 30 health supplement products, sourced from the existing supplier.
• Cash and cash equivalents increased from $18,621 as of December 31, 2024, to $68,888 as of December 31, 2025, partly due to proceeds from stock sales.

Negatives

• The company incurred a significant net loss of $231,725 in 2025, a substantial increase from the $14,980 loss in 2024.
• Net current liabilities of $22,212 as of December 31, 2025, indicate short-term liquidity challenges.
• The independent auditor expressed "substantial doubt about the Company's ability to continue as a going concern" due to recurring losses and net current liabilities.
• Material weaknesses in internal control over financial reporting were identified, including insufficient segregation of duties, lack of an independent board or audit committee, and absence of written policies.
• There is heavy reliance on related-party transactions, with 99.1% of the cost of retail trading revenue in 2025 attributed to a single vendor (Vendor A), which is owned by the CEO.
• The company explicitly states there is no scientific evidence to support the health claims of its products, relying instead on company opinion/belief.
• The company's common stock is considered a "penny stock," which may restrict trading and liquidity for investors.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring net losses and net current liabilities.
• The company operates in a highly competitive health and wellness industry, facing established competitors with significant brand recognition and financial resources.
• Heavy reliance on a single related-party supplier (Scientist Home Limited, owned by the CEO) for proprietary products creates supply chain and pricing risks.
• Lack of scientific evidence to support product health claims could lead to regulatory scrutiny, consumer dissatisfaction, and potential legal challenges.
• Regulatory compliance risks exist in Hong Kong (e.g., Personal Data (Privacy) Ordinance, Food Adulteration, Microbiological Guidelines) and potential future U.S. FDA regulations if expanding into the U.S. market.
• Identified material weaknesses in internal control over financial reporting, including insufficient segregation of duties and lack of independent oversight, pose risks to financial accuracy and fraud prevention.
• The company's status as a "penny stock" subjects it to additional sales practice requirements for broker-dealers, potentially limiting market liquidity and investor interest.
• Concentration of management power in Mr. Chan Siu Hung, who serves as CEO, CFO, President, Secretary, Treasurer, and Director, raises corporate governance concerns and potential conflicts of interest.

Future Outlook

The company plans to expand into neighboring markets across Asia, including establishing a physical health center in Singapore within the subsequent six months, contingent on sufficient funds. It also intends to facilitate sales through a secure online platform with payment gateway. Management believes existing shareholders or external financing will provide additional cash to meet the company's obligations, but no assurance can be given. The company plans to rectify identified material weaknesses in internal control by implementing an independent board, establishing written policies, and hiring additional accounting personnel upon a reverse merger or similar business acquisition.

Management Comments

• "Management believes the existing shareholders or external financing will provide additional cash to meet the Company's obligations as they become due."
• "We plan to rectify these weaknesses [in internal controls] by implementing an independent board of directors, establishing written policies and procedures for our internal control of financial reporting, and hiring additional accounting personnel at such time as we complete a reverse merger or similar business acquisition."
• "Our board of directors currently intends to retain all earnings for use in the business for the foreseeable future."

Industry Context

StockSavvy.ai notes that Scientist Home operates in a highly competitive health and wellness industry, facing established players with significant brand recognition and resources. The company's strategy of leveraging 'superior quality ingredients' and 'greater product effectiveness' without scientific evidence, alongside a reliance on word-of-mouth and CEO-led live streams, suggests a niche market approach that may struggle against mainstream, scientifically-backed competitors. The expansion into physical centers and online platforms aligns with broader industry trends towards omnichannel retail and personalized health services, but execution will be critical given the financial constraints and the company's current financial health.

Comparison to Industry Standards

• The company's significant net loss of $231,725 and the auditor's 'going concern' warning are far below industry standards for a healthy, growing enterprise in the health and wellness sector.
• The corporate governance structure, with a sole director (Mr. Chan Siu Hung) holding all executive roles and the absence of an independent board or audit committee, falls short of best practices for publicly traded companies, unlike established firms such as Johnson & Johnson or Unilever which have robust independent oversight.
• The heavy reliance on related-party transactions for nearly all cost of revenue (99.1% from a CEO-owned vendor) is a significant deviation from arm's-length dealings common in mature industries and raises concerns about potential conflicts of interest, contrasting with the transparent supply chains of industry leaders.
• The explicit statement that there is no scientific evidence to support product health claims, relying instead on 'opinion/belief,' is a stark contrast to the rigorous clinical trials and regulatory approvals (e.g., FDA, EMA) typically required for health products from major pharmaceutical or supplement companies like Pfizer or Bayer.
• The company's small scale (7 employees) and limited market presence (Hong Kong, with planned Singapore expansion) are not comparable to global health and wellness giants, which often have thousands of employees and operate across numerous international markets.

Management Changes

Corporate Governance

Legal Proceedings

• There are currently no pending legal proceedings or claims that are believed to have a material adverse effect on the business, financial condition, or operating results.

Related Party Transactions

• The company acquired 100% of Scientist Home Holding from Mr. Chan Siu Hung (CEO and Director) for $1.00 on September 26, 2024.
• The company rented office space from Tri-Hero Holdings Limited, an entity owned by Mr. Chan Siu Hung, with leases ending June 30, 2025, and June 30, 2027.
• A director (Mr. Chan Siu Hung) advanced $15,565 to the company as of December 31, 2025, which is unsecured, interest-free, and has no fixed payment term.
• A related party (Scientist Home Limited, owned by Mr. Chan Siu Hung) advanced $78,260 to the company as of December 31, 2025, as a loan, which is unsecured, interest-free, and has no fixed payment term.
• The company purchases trading goods and courier services from Scientist Home Limited (Vendor A), owned by Mr. Chan Siu Hung, accounting for 99.1% ($121,075) of the cost of revenues in 2025.
• Mr. Chan Siu Hung purchased 100,000 shares of common stock for $10 on July 3, 2024, and an additional 19,900,000 shares for $1,990 on August 14, 2024.

Stakeholder Impact

• Shareholders face significant risk of capital loss due to the explicit going concern doubt, recurring net losses, and potential dilution from future capital raises. The lack of independent governance and extensive related-party transactions may erode investor trust.
• Employees (currently 7) may face job insecurity if the company's financial health does not improve, despite plans for future hiring contingent on business growth.
• Customers may benefit from expanded product lines and new physical health centers, but the lack of scientific evidence for product claims could lead to dissatisfaction or health concerns, potentially impacting brand reputation.
• Suppliers, particularly the primary related-party supplier (Scientist Home Limited), may have an advantageous position, while other potential suppliers could face payment risks given the company's financial condition.
• Creditors face elevated risk due to the company's net current liabilities and the auditor's going concern warning, which could impact the company's ability to meet its financial obligations.

Next Steps

• Establish a physical health center in Singapore within the next six months, contingent on sufficient funds.
• Facilitate sales through a secure online platform with payment gateway.
• Increase workforce by hiring additional full-time management and administrative support personnel to meet increasing operational demands.
• Rectify internal control weaknesses by implementing an independent board of directors, establishing written policies and procedures, and hiring additional accounting personnel upon a reverse merger or similar business acquisition.
• The Board of Directors reserves the right to grant compensation (cash or stock-based awards) to directors in the future.
• The Board of Directors may award incentive bonuses to executive officers.
• The Board may award long-term, stock-based compensation to executives in the future.

Key Dates

Recommendation

The company faces severe financial distress, evidenced by a substantial net loss, net current liabilities, and an explicit 'going concern' warning from its auditor. Compounding these issues are significant corporate governance deficiencies, including a sole director holding all executive roles, no independent board or audit committee, and heavy reliance on related-party transactions for core operations. The lack of scientific backing for product claims further adds to the risk profile. While there are expansion plans, the fundamental financial and governance weaknesses make this a highly speculative and risky investment, warranting a strong sell recommendation for any existing holdings and advising against new positions.

Keywords

Health supplements, topical creams, physical check-up services, Hong Kong, going concern, SEC 10-K, financial results, corporate governance, related party transactions, internal controls, retail trading, wellness industry, Nevada corporation, Asia expansion, penny stock